Jump to content

Arcturus Therapeutics

From Wikipedia, the free encyclopedia
(Redirected from Alcobra)
Arcturus Therapeutics Holdings Inc.
Company typePublic
Nasdaq: ARCT
IndustryPharmaceutical industry
Founded2013; 11 years ago (2013)
FounderJoseph Payne and Pad Chivukula
HeadquartersSan Diego, California, US
Key people
ProductsARCT-810 for treatment of OTCD; received FDA Orphan Drug Status on 27 July 2019; Phase 1 Clinical Trials in Healthy Volunteers Initiated on 05 June 2020, ARCT-021 Vaccine for COVID-19; Phase 1/2 Initiated 22 July 2020, Phase 2 Initiated 9 January 2021
RevenueIncrease $21 Million(2019)[1]
Number of employees
124
Websitewww.arcturusrx.com

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase.[2]

History

[edit]

Founded in 2013 by Joseph Payne and Pad Chivukula, Arcturus Therapeutics is headquartered in San Diego, California, USA. Initially, they developed a proprietary lipid nanoparticle delivery system called Lunar, able to safely deliver therapeutic RNA or DNA to target cells inside a patient's body.[3]

In September 2017, Arcturus Therapeutics merged with Alcobra Ltd., an Israeli pharmaceutical company.[4] In February of 2018, Joseph Payne was dismissed as president and CEO by the Arcturus Therapeutics board of directors at that time.[5] In the aftermath, as the largest shareholder, Joseph Payne filed formal requests to hold a meeting of shareholders for the purpose of selecting new members to the Arcturus Therapeutics board of directors. Under applicable law, Arcturus’ board must have honored Payne’s request by establishing a meeting date and convening said meeting within a clearly defined timeframe. Rather than adhering to the law, the Board ignored the applicable deadlines and opted to postpone the shareholder meeting indefinitely.[6][7][8] Joseph Payne subsequently filed legal proceedings with the Israeli Court which ruled in favor of upholding shareholder rights by sanctioning the meeting of shareholders.[9]

In April of 2018, the Arcturus Therapeutics board of directors at the time filed their own complaint against Joseph Payne and his nominees to the board.[10] In May of 2018, a legal settlement was agreed upon: 4 new directors were appointed to the board (Peter Farrell, Andrew Sassine, James Barlow and Magda Marquet) resulting in the resignation of Stuart Collinson, Daniel Geffken, David Shapiro, and Craig Willett. Other key terms of the settlement agreement included mutual releases of all parties and the agreement by Arcturus Therapeutics and Joseph Payne to terminate all pending litigation.[11]

Products

[edit]

Lunar

[edit]

Lunar is a lipid nanoparticle drug delivery system which targets specific cells inside the body to deliver a payload of RNA into the cell.[12][13] Once release of the RNA into the cell occurs, the normal translational machinery of the cell can interact with the RNA to make a functional protein with a therapeutic effect. Prior to the Lunar technique, efficient in vivo delivery has also been challenging because existing lipid nanoparticles at the time could cause liver damage and elicit a strong immune response.[14]

This lipid nanoparticle delivery system has been used to deliver ornithine transcarbamylase messenger RNA to liver cells in order to treat citrin deficiency and ornithine transcarbamylase deficiency.[15] OTCD is the most common urea cycle disorder, which impacts an individual's ability to remove toxic waste products from the body. In collaboration with the Salk Institute for Biological Studies in La Jolla, California, successful delivery of a Factor IX messenger RNA to the liver was reported, which suggested viability of the approach to potentially treat diseases requiring protein replacement.[14] Researchers at the MD Anderson Cancer Center also showed the application of mRNA delivered in nanoparticles using the Lunar platform for the treatment of malignancy in intracerebral glioma.[16]

In 2019, a drug named ARCT-810 which uses Lunar, received FDA orphan drug status for treating ornithine transcarbamylase deficiency.[17] The orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States, and grants seven years of marketing exclusivity after approval.[18] On April 13, 2020, it was announced that the company's investigational new drug application for Phase 1b study in patients with OTCD was allowed to proceed by the U.S. FDA.[19] Clinical trials in patients began in June 2020.[20]

Lunar-COV19

[edit]

ARCT-021 and Starr

[edit]
Main article: ARCT-021

In response to the COVID-19 pandemic, Arcturus partnered with Duke–NUS Medical School to develop a COVID-19 vaccine using a combination of self-replicating mRNA with a Lunar delivery platform which increases the level and duration of expression of a therapeutic protein).[21] The company also partnered with Catalent and Recipharm, contract development and manufacturing organizations, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[22][23] Lunar-COV19 clinical trials in healthy volunteers began in July 2020.[24] Phase 2 clinical trials were approved in the United States and Singapore by the FDA and HSA, respectively in December 2020.[25]

Next-generations

[edit]
Main article: ARCT-154

On 2 August 2021, ARCT-154 started a clinical trial in Vietnam for next-generation development.[26] The next day, the firm announced that the application of approval for the clinical trial Phase I/II in Singapore called ARCT-165. Also application of ARCT-154 for phase I/II.[2]

Other projects

Lunar-CF is a project in collaboration with the Cystic Fibrosis Foundation to treat cystic fibrosis.[27]

Lunar-FLU is a wholly owned program to protect against the influenza virus. Arcturus is combining its self-replicating mRNA Starr technology with Lunar to develop a prophylactic vaccine against influenza.

Lunar-GSD is a project in collaboration with Ultragenyx to treat glycogen storage disease type III.[28]

Lunar-Rare is a project in collaboration with Ultragenyx to develop therapeutic candidates for rare disease targets.

Lunar-HBV is a project in collaboration with Janssen to develop medicines for the treatment of hepatitis B virus infection.[29]

Lunar-NASH is a project in collaboration with Takeda to develop medicines for non-alcoholic steatohepatitis (NASH) and other gastrointestinal disorders.[30]

Lunar-RPL is a project in collaboration with Synthetic Genomics to develop improved technology for vaccines and therapeutics.[31]

Lunar-AH is a project in collaboration with Synthetic Genomics to develop infectious disease prophylactic vaccines.

References

[edit]
  1. ^ "Arcturus Therapeutics Holdings Revenue 2012-2021 | ARCT".
  2. ^ a b "Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study". Arcturus Therapeutics. 3 August 2021.
  3. ^ Encyclopedia of Information Science and Technology, Fourth Edition. edited by Khosrow-Pour.
  4. ^ "Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge | Arcturus Therapeutics, Inc". ir.arcturusrx.com. Retrieved 2022-03-25.
  5. ^ "Arcturus Therapeutics board fires CEO". Globes. 2018-05-02. Retrieved 2022-03-25.
  6. ^ Payne, Joseph (2018-04-13). "Arcturus Therapeutics Founder Joseph Payne Disappointed by Board's Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability". GlobeNewswire News Room (Press release). Retrieved 2022-03-25.
  7. ^ Payne, Joseph (2018-04-23). "Arcturus Therapeutics Founder Joseph Payne Dismisses Board's Baseless Lawsuit as Desperate Entrenchment Tactic". GlobeNewswire News Room (Press release). Retrieved 2022-03-25.
  8. ^ Payne, Joseph (2018-05-02). "Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board's Egregious Attempt to Dilute Shareholders". GlobeNewswire News Room (Press release). Retrieved 2022-03-25.
  9. ^ Payne, Joseph (2018-05-14). "Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Members". GlobeNewswire News Room (Press release). Retrieved 2022-03-25.
  10. ^ Payne, Joseph (2018-05-23). "Arcturus Therapeutics Founder Joseph Payne Calls for an End to Company's Frivolous and Costly Lawsuits; Applauds Court Decision and Welcomes June 25, 2018 EGM Date". GlobeNewswire News Room (Press release). Retrieved 2022-03-25.
  11. ^ Payne, Joseph (2018-05-29). "Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne". GlobeNewswire News Room (Press release). Retrieved 2022-03-25.
  12. ^ Teruki, Yanagi (28 June 2016). "Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1/PCTK1/Cdk16 Inhibits In Vivo Cancer Growth". Molecular Therapy: Nucleic Acids. 5 (6): e327. doi:10.1038/mtna.2016.40. PMC 5022131. PMID 27351680.
  13. ^ Stein, Richard (26 May 2017). "Better Targeting, Delivery of RNAi Therapies". Genetic Engineering & Biotechnology News. 37 (11): 1, 14–17. doi:10.1089/gen.37.11.02.
  14. ^ a b Ramaswamy, Suvasini (7 March 2017). "Systemic delivery of factor IX messenger RNA for protein replacement therapy". PNAS. 114 (10): E1941–E1950. Bibcode:2017PNAS..114E1941R. doi:10.1073/pnas.1619653114. PMC 5347596. PMID 28202722.
  15. ^ Damase, Tulsi Ram; Sukhovershin, Roman; Boada, Christian; Taraballi, Francesca; Pettigrew, Roderic I.; Cooke, John P. (2021). "The Limitless Future of RNA Therapeutics". Frontiers in Bioengineering and Biotechnology. 9: 628137. doi:10.3389/fbioe.2021.628137. ISSN 2296-4185. PMC 8012680. PMID 33816449.
  16. ^ Yaghi, Nasser (1 March 2017). "Immune modulatory nanoparticle therapeutics for intracerebral glioma". Neuro-Oncology. 9 (3): 372–382. doi:10.1093/neuonc/now198. PMC 5464307. PMID 27765835.
  17. ^ "Arcturus Therapeutics Receives Orphan Drug Designation". Drug Development and Delivery. 28 June 2019.
  18. ^ "Designating an Orphan Product: Drugs and Biological Products". FDA Website. 24 Jul 2019.
  19. ^ "Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With OTC Deficiency - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-27.
  20. ^ "Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency". Arcturus Therapeutics. Retrieved 2020-07-27.
  21. ^ "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. 15 April 2020. Retrieved 27 April 2020.
  22. ^ "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. 2020-05-06. Retrieved 2020-05-08.
  23. ^ "Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR[®]-COV19 (ARCT-021) vaccine candidate". Recipharm. Retrieved 2021-03-12.
  24. ^ "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. Retrieved 2020-07-27.
  25. ^ Arcturus Therapeutics, Inc. (2021-03-02). "A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants". Retrieved 12 March 2021.
  26. ^ "Arcturus to start clinical trial of COVID-19 vaccine in Vietnam". Reuters. 2 August 2021. Retrieved 3 August 2021.
  27. ^ Lopez, Jose Marques (25 June 2018). "RNA Therapy for CF shows promise in preclinical studies". Cystic Fibrosis News Today.
  28. ^ "mRNA therapeutics". Adis Insights, Springer. Arcturus Therapeutics/Ultragenyx Pharmaceutical. 21 June 2019.
  29. ^ Adams, Ben (19 October 2017). "Johnson & Johnson, RNA biotech Arcturus combine for hepatitis B work". Fierce Biotech.
  30. ^ Elvidge, Suzanne. "Mixed results in NASH for Gilead". BioPharma Drive.
  31. ^ Kotok, Allan (31 October 2017). "RNA Meds Companies Partner on Human, Animal Vaccines". Science Business.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Arcturus_Therapeutics&oldid=1252078570"